Neuronal Alpha-Synuclein Disease

Last updated

Neuronal Alpha-Synuclein Disease (NSD) is a proposed new combined definition of Parkinson's disease and Dementia with Lewy bodies based on biology instead of symptomatology. [1] [2] [3] [4]

References

  1. ↑ "Major Shift in the Clinical Definition of PD Triggers Debate". Medscape. Retrieved 2024-12-26.
  2. ↑ "New Parkinson's Definition Proposed Based on Biomarkers". January 26, 2024.
  3. ↑ Simuni, Tanya; Chahine, Lana M; Poston, Kathleen; Brumm, Michael; Buracchio, Teresa; Campbell, Michelle; Chowdhury, Sohini; Coffey, Christopher; Concha-Marambio, Luis; Dam, Tien; DiBiaso, Peter; Foroud, Tatiana; Frasier, Mark; Gochanour, Caroline; Jennings, Danna (2024-02-01). "A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research". The Lancet Neurology. 23 (2): 178–190. doi:10.1016/S1474-4422(23)00405-2. ISSN   1474-4422. PMID   38267190. Archived from the original on 2024-02-01. Retrieved 2024-12-26.
  4. ↑ Pagano, Gennaro; Dam, Tien; Kerchner, Geoffrey A.; Galpern, Wendy R.; Biagioni, Milton; Karan, Rajesh; Jennings, Danna; Peterschmitt, M. Judith; Nikolcheva, Tania; Brundin, Patrik (2024-12-20). "Biologically defined neuronal synuclein disease as a tool to advance drug development". npj Parkinson's Disease. 10 (1): 235. doi:10.1038/s41531-024-00845-5. ISSN   2373-8057. PMC   11662015 . PMID   39706882.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.